Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Posaconazole.

Gillian M Keating1

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 22, 2005
PubMed
Summary
This summary is machine-generated.

Posaconazole shows significant efficacy in treating invasive fungal infections, particularly in patients refractory to other antifungals. This triazole antifungal agent demonstrated high success rates across various mycoses, including aspergillosis and zygomycosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) pose a significant threat, especially in immunocompromised patients.
  • Limited treatment options exist for patients with IFIs refractory to or intolerant of standard antifungal therapies.
  • Posaconazole, a triazole antifungal, offers broad-spectrum activity against various fungi.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of posaconazole in patients with IFIs refractory to or intolerant of other antifungal agents.
  • To assess posaconazole's effectiveness across a spectrum of fungal infections, including aspergillosis, zygomycosis, and candidiasis.

Main Methods:

  • An open-label, multicentre, phase III study involving 330 patients receiving posaconazole and 279 external controls.

Related Experiment Videos

  • Phase II study in febrile neutropenia and a phase III study in HIV-infected patients with candidiasis were also referenced.
  • Data collected included global response success rates at end-of-therapy and clinical response rates.

    • Main Results:

    • Significantly higher success rates for posaconazole in aspergillosis (42% vs. 26%) compared to external controls.
    • High success rates observed for posaconazole in zygomycosis (54%), fusariosis (46%), Pseudallescheria infection (43%), phaeohyphomycosis (80%), and histoplasmosis (100%).
    • Effective in refractory infections: candidiasis (48%), coccidioidomycosis (69%), cryptococcal infection (48%), chromoblastomycosis/mycetoma (82%); 81% success in febrile neutropenia; 75% clinical response in HIV-associated candidiasis.

    Conclusions:

    • Posaconazole demonstrates clinically relevant activity and is generally well-tolerated in patients with invasive fungal infections, including those refractory to other treatments.
    • The drug shows promise for various mycoses and in specific patient populations like febrile neutropenia and advanced HIV.
    • Oral posaconazole suspension is a viable treatment option, even for long-term use (>1 year).